Migayron et al. Front Immunol➜ DOI: 10.3389/fimmu.2024.1405215Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?This is an interesting review which approaches indirectly some of the paradoxical findings observed using targeted therapies in AD. Silverberg et al JAAD➜ DOI: 10.1016/j.jaad.2024.05.023Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis [...] Read More
Carmanius et al, JEADV 2024➜ DOI: 10.1111/jdv.20076A cross-sectional study based on the 24-year follow-up from the population-based birth cohort linked with dispensing data from the National Swedish Drug Register confirms that a large proportion of young adults with AD is undertreated or untreated. Kook et al, JEADV 2024➜ DOI: 10.1111/jdv.20053Misdiagnosis of AD or confounding skin diseases in [...] Read More
Federica Casetti, Cristina Has➜ First published: 03 March 2024 - DOI: 10.1111/ddg.15358Dupilumab improves congenital ichthyosis in the context of a filaggrin pathogenic variant. This report from Germany confirms other reports of a response of rare ichthyotic conditions such as Netherton’s syndrome and trichothiodystrophy to targeting IL-4Rα, and that the common FLG mutations may accentuate the inflammatory phenotype [...] Read More
Docampo-Simon et al Int J Dermatol 2024➜ First published: 03 March 2024 - DOI: 10.1111/ijd.17100Spanish investigators delineate based on a small case series psoriasis dermatitis, a common ambiguous phenotype of early forms of both psoriasis and atopic dermatitis in children; this phenotype was already well recognized in infants, but this study adds arguments for a later [...] Read More